Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-11-08 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Eureka Strategic Collaboration (supplementary announcement) 3 pages 126.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement regarding a strategic collaboration between Imugene Limited and Eureka Therapeutics. It provides detailed information about the collaboration, funding, intellectual property rights, and background on the companies and technologies involved. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a report publication notice. The content focuses on a corporate partnership and research collaboration update, which fits best under Capital/Financing Update (CAP) as it relates to strategic collaboration and funding alignment. The document length is sufficient and contains substantive information about the collaboration rather than just an announcement of a report or a brief notice.
2021-11-08 English
Application for quotation of securities - IMU 9 pages 32.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and whether the securities rank equally with existing shares. The document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It does not contain financial statements, management discussion, or audit information. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2021-11-04 English
Imugene and Eureka Therapeutics onCARlytics Collaboration 3 pages 143.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing a strategic collaboration between Imugene and Eureka Therapeutics to advance oncolytic virus and T-cell therapy in solid tumors. It includes information about the collaboration, scientific background, company descriptions, and contact details. There are no financial statements, quarterly or annual results, nor is there any indication of a report being attached or published. The content is a corporate announcement about a strategic partnership and research collaboration, which fits best under a general regulatory announcement category. It is not a financial report, earnings release, or management discussion. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-10-31 English
Investor webinar Imugene & Eureka Therapeutics Collaboration 2 pages 113.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about an investor webinar discussing a strategic collaboration between Imugene and Eureka Therapeutics. It invites investors to register for the webinar and mentions that a recording will be available after the session. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other specific regulatory content. The document is short (3246 characters) and primarily serves as an announcement of an event (investor webinar) rather than a report or detailed presentation. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2021-10-31 English
Investor Presentation Imugene Eureka Therapeutics 18 pages 2.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Imugene Limited dated 01 November 2021. It contains extensive information about the company's technology, partnerships, clinical pipeline, scientific data, milestones, and financial summary including share price and market capitalization. The content is structured as a presentation with slides, disclaimers, and detailed scientific and business information aimed at investors. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting result or management change announcement. The document is clearly a detailed investor-focused presentation, likely used to inform or update investors on company strategy, technology, and financial overview. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-10-31 English
Application for quotation of securities - IMU 9 pages 32.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, issue prices, and the classes of securities involved. There is no indication of financial performance data, management discussion, or earnings results. The document is an official announcement related to the listing and quotation of new securities on the ASX (Australian Securities Exchange). This fits the category of Share Issue/Capital Change, as it announces new share issues and changes in capital structure due to option exercises and conversions.
2021-10-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.